Blocking tau, a hallmark of Alzheimer’s disease, may benefit ALS patients.
- The main driver of Alzheimer’s disease is excessive inflammation in the brain that is triggered by cells called astrocytes and microglia in response to high levels of amyloid beta deposits and tau tangles.
- New research reveals that a subset of astrocytes releases a molecule called interleukin-3 that instructs microglia to adopt a protective response and clear away amyloid beta deposits and tau tangles.
- Interleukin-3 may hold promise as a new therapeutic intervention in Alzheimer’s disease.
Cameron McAlpine, PhD
Our findings suggest that communication between astrocytes and microglia, via IL-3, is an important mechanism that wards off Alzheimer’s disease by instructing microglia to adapt protective functions. With further study, IL-3 signaling may provide a new therapeutic opportunity to combat neurological diseases.
Center for Systems Biology, Massachusetts General Hospital
BOSTON – New research in humans and mice identifies a particular signaling molecule that can help modify inflammation and the immune system to protect against Alzheimer’s disease. The work, which was led by investigators at Massachusetts General Hospital (MGH), is published in Nature.
Cognitive decline associated with Alzheimer’s disease develops when neurons begin to die. “Neuron death can be caused by improper immune responses and excessive neuroinflammation—or inflammation in the brain—triggered by high levels of amyloid beta deposits and tau tangles, two hallmarks of Alzheimer’s disease,” explains the paper’s co–senior author Filip Swirski, PhD, who conducted the work while a principal investigator in the Center for Systems Biology at MGH.
“Once neurons start dying in increasing amounts, brain cells called microglia and astrocytes—which are normally nurturing cells that clean up debris—become activated to cause neuroinflammation in an attempt to protect the brain. They are evolutionarily programmed to wipe out a brain region where there is excess neuronal cell death because it may be due to an infection, which must be stopped from spreading,” explains co–senior author Rudolph Tanzi, PhD, co-director of the McCance Center for Brain Health at MGH.
In the case of Alzheimer’s disease, the neuronal cell death brought on by amyloid beta deposits and tau tangles activates this response. “As neuroinflammation ensues, the amount of cell death is at least 10 times higher than that which was caused by plaques and tangles,” says Tanzi. “In fact, without the induction of neuroinflammation, there would be no symptoms of dementia. We know this from ‘resilient’ brains, in which there are lots of plaques and tangles in an individual’s brain but no symptoms at death because there was minimal or no neuroinflammation.” Tanzi provides an analogy, noting that amyloid beta is the “match” that lights the spreading “brushfires” of tangles, but only when this leads to increasing numbers of “forest fires” through neuroinflammation that is activated by microglia and astrocytes does one lose enough neurons to suffer cognitive decline and dementia.
This new study in Nature revealed that a subset of astrocytes actually tries to put out the fire by releasing a molecule called interleukin-3 (IL-3), which then converts killer microglial cells back into nurturing and protective cells that no longer wipe out neurons and instead focus on cleaning out amyloid beta deposits and tau tangles.
“There may be important clinical implications to knowing that astrocytes talk to microglia via IL-3 to educate the microglia and help them decrease the severity of Alzheimer’s disease,” says Swirski. “We can now think about how to use IL-3 to not only help curb the neuroinflammation that carries out the bulk of neuronal cell death in Alzheimer’s disease, but also to entice microglia to once again take on the beneficial task of clearing away the deposits and tangles that are the initiating pathology of Alzheimer’s disease.”
“It was surprising to find IL-3 in the brain,” says first author Cameron McAlpine, PhD, then an instructor in the Center for Systems Biology. “Our findings suggest that communication between astrocytes and microglia, via IL-3, is an important mechanism that wards off Alzheimer’s disease by instructing microglia to adapt protective functions. With further study, IL-3 signaling may provide a new therapeutic opportunity to combat neurological diseases.”
Tanzi is vice chair of Neurology and director of the Genetics and Aging Research Unit at MGH. Swirski is director of the Cardiovascular Research Institute and professor of Medicine (Cardiology) and Diagnostic Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai in New York City. McAlpine is assistant professor of Medicine (Cardiology) and Neuroscience at the Icahn School of Medicine. Study co-authors include Joseph Park, Ana Griciuc, Eunhee Kim, Se Hoon Choi, PhD, Yoshiko Iwamoto, Máté G. Kiss, Kathleen A. Christie, Claudio Vinegoni, PhD, Wolfram C. Poller, John E. Mindur, Christopher T. Chan, Shun He, Henrike Janssen, Lai Ping Wong, Jeffrey Downey, Sumnima Singh, Atsushi Anzai, PhD, Florian Kahles, MD, Mehdi Jorfi, Paolo Fumene Feruglio, Ruslan I. Sadreyev, Ralph Weissleder, MD, PhD, Benjamin P. Kleinstiver, and Matthias Nahrendorf, MD, PhD.
The study was funded by the Cure Alzheimer’s Fund, the National Institutes of Health, the Patricia and Scott Eston MGH Research Scholar, a Canadian Institutes of Health Research Banting Fellowship, and a Kirschstein National Research Service Award Individual Predoctoral Fellowship.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Aug | 20 | 2021
Irisin is an important mediator of the neuroprotective benefits of exercise in the brain, holding potential for treating Alzheimer’s disease and other neurodegenerative diseases.
- Press Release
- Jul | 8 | 2021
La terapia génica con "dedos de cinc" puede ayudar a tratar la enfermedad de Alzheimer, según un estudio en animales
Los investigadores han utilizado una estrategia de ingeniería genética para reducir drásticamente los niveles de tau—una proteína clave que se acumula y se enreda en el cerebro durante el desarrollo de la enfermedad de Alzheimer—en un modelo animal de la enfermedad.
- Press Release
- Jul | 6 | 2021
There is no clinical evidence that the monoclonal antibody aducanumab is beneficial to patients with cerebral amyloid angiopathy, according to officers with the International Cerebral Amyloid Angiopathy Association.
- Press Release
- May | 19 | 2021
A key protein must be cut to create amyloid beta. Groundbreaking work identifies the “lipid raft” in nerve cells where this process occurs, which could offer new targets for drug therapy.
- Press Release
- May | 12 | 2021
During the development and progression of Alzheimer’s disease, a protein called tau accumulates and spreads in the brain. Understanding the mechanisms behind tau spread—and its consequences—may point to new prevention and treatment strategies for Alzheimer’s disease and other forms of dementia.